ACRS — Aclaris Therapeutics Share Price
Last Trade - 00:00- $819.53m
- $598.59m
- $6.63m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 1.68 | 6.15 | 4.23 | 6.48 | 7.16 | 7.6 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drug candidates for immuno-inflammatory diseases. Its drug candidates include ATI-450, ATI-1777, ATI-2138 and Undisclosed- Gut Restricted Program. Its ATI-450 is an investigational oral, small molecule selective mitogen-activated protein kinase-activated protein kinase 2, or MK2, inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777 is an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. Its ATI-2138 is an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, as al treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases.
Directors
- Christopher Molineaux NEC (55)
- Neal Walker (51)
- Frank Ruffo CFO (55)
- Kamil Ali-Jackson OTH (62)
- David Gordon (52)
- Maxine Gowen (62)
- William Humphries (54)
- Anand Mehra IND (45)
- Vincent Milano (57)
- Andrew Powell (63)
- Bryan Reasons (53)
- Andrew Schiff (55)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- July 13th, 2012
- Public Since
- October 7th, 2015
- No. of Shareholders
- 56
- No. of Employees
- 60
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 61,204,987
- Address
- 640 Lee Rd Ste 200, WAYNE, 19087-5636
- Web
- https://www.aclaristx.com/
- Phone
- +1 4843247933
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ACRS
Upcoming events for ACRS
Q3 2021 Aclaris Therapeutics Inc Earnings Release
Similar to ACRS
4D MOLECULAR THERAPEUTICS ORD
NASDAQ Global Select Market
ABCELLERA BIOLOGICS ORD
NASDAQ Global Select Market
ABSCI ORD
NASDAQ Global Select Market
ACADIA PHARMACEUTICALS ORD
NASDAQ Global Select Market
ACHILLES THERAPEUTICS ADS
NASDAQ Global Select Market
FAQ
As of Today at 19:54 UTC, shares in Aclaris Therapeutics are trading at $13.39. This share price information is delayed by 15 minutes.
Shares in Aclaris Therapeutics last closed at $13.39 and the price had moved by +464.98% over the past 365 days. In terms of relative price strength the Aclaris Therapeutics share price has outperformed the S&P500 Index by +328.64% over the past year.
The overall consensus recommendation for Aclaris Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aclaris Therapeutics does not currently pay a dividend.
Aclaris Therapeutics does not currently pay a dividend.
Aclaris Therapeutics does not currently pay a dividend.
To buy shares in Aclaris Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $13.39, shares in Aclaris Therapeutics had a market capitalisation of $819.53m.
Here are the trading details for Aclaris Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ACRS
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Aclaris Therapeutics does not currently have a style classification.
The analyst consensus target price for shares in Aclaris Therapeutics is $34.80. That is 159.9% above the last closing price of $13.39.
Analysts covering Aclaris Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.46 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aclaris Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -48.2%.
As of the last closing price of $13.39, shares in Aclaris Therapeutics were trading -19.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Aclaris Therapeutics.
Aclaris Therapeutics' management team is headed by:
- Christopher Molineaux - NEC
- Neal Walker -
- Frank Ruffo - CFO
- Kamil Ali-Jackson - OTH
- David Gordon -
- Maxine Gowen -
- William Humphries -
- Anand Mehra - IND
- Vincent Milano -
- Andrew Powell -
- Bryan Reasons -
- Andrew Schiff -
We do not have data on Aclaris Therapeutics' shareholders